Pharmaceutical manufacturing

FILE - This Friday, Oct. 10, 2008, file photo illustration shows Johnson & Johnson products, in Philadelphia. Johnson & Johnson is topping profit and revenue expectations for the first quarter partially on strong sales of its psoriasis treatment, Stelara. The New Brunswick, N.J., company on Tuesday, April 16, 2019 posted profit of $3.75 billion, or $1.39 per share. Earnings, adjusted for amortization costs and research and development costs, were $2.10 per share, or 7 cents better that Wall Street expected, according to a survey by Zacks Investment Research. (AP Photo/Matt Rourke, File)
April 16, 2019 - 7:04 am
Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson's first-quarter profit down 14%, but the health care giant still beat profit and revenue expectations. The maker of Tylenol and psoriasis drug Stelara on Tuesday said unfavorable currency exchange rates...
Read More
In this June 15, 2018 photo, pharmaceuticals are seen in North Andover, Mass. As Congress and the Trump administration aim to curb spiraling drug costs, outside groups like the Alliance for Patient Access are raising their voices as they seek to sway the outcome. But not all of these organizations are clear about who they actually represent. Their names can obscure the source of the message and they’re cagey about where all of their money comes from. (AP Photo/Elise Amendola)
March 18, 2019 - 8:54 am
WASHINGTON (AP) — As ominous music plays in the background, the narrator of a radio ad warns that a Trump administration proposal to apply international pricing to certain Medicare drugs would be a nightmare for seniors. The one-minute spot is the handiwork of the Alliance for Patient Access, a...
Read More
March 12, 2019 - 5:58 am
MINNETONKA, Minn. (AP) — The nation's largest health insurer is expanding a program that passes rebates from drugmakers directly to the people that use their medications. Beginning next year, all employer-sponsored health care plans that use UnitedHealthcare must give point-of-sale discounts...
Read More
FILE- This April 26, 2017, file photo shows the Eli Lilly and Co. corporate headquarters in Indianapolis. Eli Lilly is offering a half-price version of its top-selling insulin Humalog as drugmakers face growing pressure to control prices. The drugmaker says it will introduce a version of the diabetes treatment called Insulin Lispro with a list price 50 percent lower than its current rate, about $275 per vial. (AP Photo/Darron Cummings, File)
March 04, 2019 - 1:32 pm
INDIANAPOLIS (AP) — Eli Lilly is offering a half-price version of a top-selling insulin to ease the financial strain imposed on some patients, but an advocacy group says much bigger changes are needed. The drugmaker said Monday it will introduce a version of the diabetes treatment Humalog that will...
Read More
From l-r., Richard A. Gonzalez , Chairman and Chief Executive Officer AbbVie Inc., Pascal Soriot, Executive Director and Chief Executive Officer AstraZeneca, Giovanni Caforio, M.D. Chairman of the Board and Chief Executive Officer Bristol-Myers Squibb Co., Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson, Kenneth C. Frazier, Chairman and Chief Executive Officer Merck & Co., Inc., Albert Bourla, DVM, Ph.D. Chief Executive Office Pfizer, Olivier Brandicourt, M.D. Chief Executive Officer Sanofi, prepare to testify before the Senate Finance Committee hearing on drug prices, Tuesday, Feb. 26, 2019 on Capitol Hill in Washington. (AP Photo/Pablo Martinez Monsivais)
February 26, 2019 - 12:42 pm
WASHINGTON (AP) — Drawing from their personal experiences, senators on Tuesday chastised drug company executives over the high cost of prescription drugs, as the company officials cautioned that heavy-handed congressional action could jeopardize medical breakthroughs going forward. Tuesday's Senate...
Read More
From l-r., Richard A. Gonzalez , Chairman and Chief Executive Officer AbbVie Inc., Pascal Soriot, Executive Director and Chief Executive Officer AstraZeneca, Giovanni Caforio, M.D. Chairman of the Board and Chief Executive Officer Bristol-Myers Squibb Co., Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson, Kenneth C. Frazier, Chairman and Chief Executive Officer Merck & Co., Inc., Albert Bourla, DVM, Ph.D. Chief Executive Office Pfizer, Olivier Brandicourt, M.D. Chief Executive Officer Sanofi, wait to testify before the Senate Finance Committee hearing on drug prices, Tuesday, Feb. 26, 2019 on Capitol Hill in Washington. (AP Photo/Pablo Martinez Monsivais)
February 26, 2019 - 11:41 am
WASHINGTON (AP) — The Latest on top pharmaceutical executives testifying before Senate lawmakers on rising drug prices (all times local): 12:40 p.m. Seven top pharmaceutical executives are telling lawmakers they do not withhold their drugs from potential competitors to stop them from developing...
Read More
February 24, 2019 - 3:43 pm
WASHINGTON (AP) — With health care a top issue for American voters, Congress may actually be moving toward doing something this year to address the high cost of prescription drugs. President Donald Trump, Democrats trying to retire him in 2020, and congressional incumbents of both parties all say...
Read More
FILE - This May 1, 2018 file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck & Co. reports earnings Friday, Feb. 1, 2019. (AP Photo/Seth Wenig, File)
February 01, 2019 - 8:58 am
Higher medicine sales and lower restructuring and other costs lifted drugmaker Merck to a $1.83 billion profit in the fourth quarter, as it edged past Wall Street expectations. The maker of blockbuster cancer drug Keytruda and Januvia diabetes pills lost $1.05 billion a year earlier, when it had a...
Read More
FILE- In this Oct. 26, 2018, file photo Health and Human Services Secretary Alex Azar speaks about proposed reforms to Medicare Part B drug pricing policies at the Brookings Institute in Washington. The Trump administration says it is moving ahead with a plan to let patients directly receive prescription drug discounts negotiated behind-the-scenes between drugmakers, middlemen, and insurers. Azar said Thursday, Jan. 31, 2019, the proposed regulation would encourage the major industry players to channel any such discounts to consumers when they purchase their prescriptions. (AP Photo/Alex Brandon, File)
January 31, 2019 - 11:50 pm
WASHINGTON (AP) — The Trump administration has unveiled a plan to channel now-hidden prescription drug rebates directly to patients, saying it would bypass middlemen and lower prices for consumers. The proposed regulation from Health and Human Services Secretary Alex Azar would eliminate behind-the...
Read More
FILE- In this Oct. 26, 2018, file photo Health and Human Services Secretary Alex Azar speaks about proposed reforms to Medicare Part B drug pricing policies at the Brookings Institute in Washington. The Trump administration says it is moving ahead with a plan to let patients directly receive prescription drug discounts negotiated behind-the-scenes between drugmakers, middlemen, and insurers. Azar said Thursday, Jan. 31, 2019, the proposed regulation would encourage the major industry players to channel any such discounts to consumers when they purchase their prescriptions. (AP Photo/Alex Brandon, File)
January 31, 2019 - 6:55 pm
WASHINGTON (AP) — The Trump administration Thursday unveiled a plan to channel now-hidden prescription drug rebates directly to patients, saying it would bypass middlemen and lower prices for consumers. The proposed regulation from Health and Human Services Secretary Alex Azar would eliminate...
Read More

Pages